Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium.
Javaid MK, Boyce A, Appelman-Dijkstra N, Ong J, Defabianis P, Offiah A, Arundel P, Shaw N, Pos VD, Underhil A, Portero D, Heral L, Heegaard AM, Masi L, Monsell F, Stanton R, Dijkstra PDS, Brandi ML, Chapurlat R, Hamdy NAT, Collins MT.
Orphanet J Rare Dis. 2019 Jun 13;14(1):139. doi: 10.1186/s13023-019-1102-9.
McCune-Albright Syndrome: A Case Report and Review of Literature.
Nicolaides NC, Kontou M, Vasilakis IA, Binou M, Lykopoulou E, Kanaka-Gantenbein C.
Int J Mol Sci. 2023 May 9;24(10):8464. doi: 10.3390/ijms24108464.
The Clinical Spectrum of McCune-Albright Syndrome and Its Management.
Spencer T, Pan KS, Collins MT, Boyce AM.
Horm Res Paediatr. 2019;92(6):347-356. doi: 10.1159/000504802. Epub 2019 Dec 19.
Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Galpha s Activation.
Boyce AM, Collins MT.
Endocr Rev. 2020 Apr 1;41(2):345-70. doi: 10.1210/endrev/bnz011.
[McCune-Albright syndrome: a case report and literature review].
Chabouni H, Jemaa MB, Ghorbel M, Trigui M, Zribi W, Zribi M, Ayadi K, Aoui M, Keskes H.
Pan Afr Med J. 2023 Sep 22;46:33. doi: 10.11604/pamj.2023.46.33.35274. eCollection 2023.
McCune-Albright syndrome in adulthood.
Chanson P, Salenave S, Orcel P.
Pediatr Endocrinol Rev. 2007 Aug;4 Suppl 4:453-62.
[McCune-Albright syndrome].
Yamada N, Tatsuno I.
Nihon Rinsho. 2006 Jun 28;Suppl 2:126-30.
McCune-Albright syndrome.
Feuillan PP.
Curr Ther Endocrinol Metab. 1997;6:235-9.
Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune-Albright Syndrome.
Tucker-Bartley A, Selen DJ, Golden E, van Gool R, Ebb D, Mannstadt M, Upadhyay J.
Int J Mol Sci. 2023 Jan 29;24(3):2550. doi: 10.3390/ijms24032550.
McCune-Albright syndrome.
Dumitrescu CE, Collins MT.
Orphanet J Rare Dis. 2008 May 19;3:12. doi: 10.1186/1750-1172-3-12.
